-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chimeric antigen receptor (CAR) T cells (CAR-T) induce durable responses in patients with refractory hematological malignancies
Interleukin-2 (IL-2) is an important cytokine that activates T cells and is considered a way to treat cancer
In a new study, researchers from Synthekine in the United States report an orthogonal IL-2 receptor/ligand system that can specifically control the proliferation and activation of CAR-T cells in vivo.
CAR-T cell manufacturing pipeline, image from Gene Therapy, 2021, doi:10.
T cells were genetically engineered to express the receptor hoRb, which can only be activated by STK-009
In a preclinical model of human CAR-refractory lymphoma, STK-009 treatment resulted in systemic and intratumoral proliferation and activation of hoRb-expressing anti-CD19-CD28ζ CAR-T cells (SYNCAR)
References:
Paul-Joseph Aspuria et al.